Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,610 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Farletuzumab in lung cancer.
Thomas A, Maltzman J, Hassan R. Thomas A, et al. Lung Cancer. 2013 Apr;80(1):15-8. doi: 10.1016/j.lungcan.2012.12.021. Epub 2013 Jan 26. Lung Cancer. 2013. PMID: 23357463 Free PMC article. Review.
Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study.
Thomas A, Mian I, Tlemsani C, Pongor L, Takahashi N, Maignan K, Snider J, Li G, Frampton G, Ali S, Kim S, Nichols S, Rajapakse V, Guha U, Sharon E, Fujimoto J, Moran CA, Wistuba II, Wei JS, Khan J, Szabo E, Torres AZ, Carson KR. Thomas A, et al. Chest. 2020 Oct;158(4):1723-1733. doi: 10.1016/j.chest.2020.04.068. Epub 2020 May 26. Chest. 2020. PMID: 32464188 Free PMC article.
Lenvatinib for thymic carcinomas.
Takahashi N, Thomas A. Takahashi N, et al. Among authors: thomas a. Lancet Oncol. 2020 Jun;21(6):745-746. doi: 10.1016/S1470-2045(20)30213-8. Lancet Oncol. 2020. PMID: 32502438 No abstract available.
Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumors.
Takahashi N, Rajapakse VN, Pongor L, Kumar S, Tlemsani C, Erwin-Cohen R, Young HA, Hewitt S, Wei JS, Khan J, Villarino AV, Trepel JB, Thomas A. Takahashi N, et al. Among authors: thomas a. Cold Spring Harb Mol Case Stud. 2020 Oct 7;6(5):a005678. doi: 10.1101/mcs.a005678. Print 2020 Oct. Cold Spring Harb Mol Case Stud. 2020. PMID: 33028646 Free PMC article.
Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies.
Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, Figg WD, Pommier Y, Calzone K, Steinberg SM, Wei JS, Guha U, Turner CE, Khan J, Thomas A. Tlemsani C, et al. Among authors: thomas a. Sci Transl Med. 2021 Jan 27;13(578):eabc7488. doi: 10.1126/scitranslmed.abc7488. Sci Transl Med. 2021. PMID: 33504652 Free PMC article.
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M, Wilson KM, Zhang Y, Beck E, Sciuto L, Nichols S, Elenbaas B, Puc J, Dahmen H, Zimmermann A, Varonin J, Schultz CW, Kim S, Shimellis H, Desai P, Klumpp-Thomas C, Chen L, Travers J, McKnight C, Michael S, Itkin Z, Lee S, Yuno A, Lee MJ, Redon CE, Kindrick JD, Peer CJ, Wei JS, Aladjem MI, Figg WD, Steinberg SM, Trepel JB, Zenke FT, Pommier Y, Khan J, Thomas CJ. Thomas A, et al. Among authors: thomas cj. Cancer Cell. 2021 Apr 12;39(4):566-579.e7. doi: 10.1016/j.ccell.2021.02.014. Cancer Cell. 2021. PMID: 33848478 Free PMC article.
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Jo U, Senatorov IS, Zimmermann A, Saha LK, Murai Y, Kim SH, Rajapakse VN, Elloumi F, Takahashi N, Schultz CW, Thomas A, Zenke FT, Pommier Y. Jo U, et al. Among authors: thomas a. Mol Cancer Ther. 2021 Aug;20(8):1431-1441. doi: 10.1158/1535-7163.MCT-20-1026. Epub 2021 May 27. Mol Cancer Ther. 2021. PMID: 34045232 Free PMC article.
9,610 results